Internship

2025 Summer Internship

Computational Chemistry & Artificial Intelligence

Posted on 3/13/2025

Arvinas

Arvinas

201-500 employees

Develops therapies targeting disease-causing proteins

No salary listed

No H1B Sponsorship

Remote in USA

Candidates must be based in the U.S.

Category
AI Research
Computational Biology
AI & Machine Learning
Biology & Biotech
Required Skills
Python
Git
Requirements
  • A knowledge of organic chemistry at the undergraduate level or higher is required.
  • Proficiency in Python programming required.
  • Experience with a cheminformatics toolkit (RDKit, Openeye, Schrodinger, etc.) is required.
  • Experience using version control (GitHub, GitLab, Bitbucket, etc.) required.
  • Must be able to work effectively in both independent and team contexts.
  • Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship.
Responsibilities
  • Explore generative AI approaches for de novo drug design and synthetic pathway generation.
  • Dive deep into molecular datasets, creating statistically rigorous training, validation, and test sets to optimally retrain generative AI models for real-world prediction and generation tasks.
  • Run generative methods on protein targets of interests and evaluate the quality of the results with an emphasis on synthetic accessibility of the designed molecules.
  • Prepare and present results at an internal Arvinas function at the conclusion of the internship.
Desired Qualifications
  • Experience working on medicinal chemistry projects is desirable.
  • Knowledge of and experience with at least one ML framework (TensorFlow, PyTorch or Keras) is desirable.
  • Knowledge of RNNs, LSTMs, Transformers and LLMs is desirable.

Arvinas develops therapies aimed at treating serious diseases caused by harmful proteins. The company uses a special technology called PROTAC® to create protein degraders that work by utilizing the body's natural system to eliminate these unwanted proteins. This approach allows for targeted treatment of conditions like cancer and neurodegenerative disorders. Unlike many other biopharmaceutical companies, Arvinas focuses specifically on the degradation of disease-causing proteins, which sets it apart in the biotechnology field. The goal of Arvinas is to enhance patient outcomes by offering effective therapies that tackle the root causes of debilitating diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

New Haven, Connecticut

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase 3 results for vepdegestrant highlight PROTAC's potential in breast cancer treatment.
  • Arvinas' $1.16 billion deal with Novartis boosts its financial and market position.
  • Expansion at Science Park enhances R&D capabilities, accelerating new therapy development.

What critics are saying

  • Increased competition from companies like C4 Therapeutics may impact market share.
  • Regulatory scrutiny could delay clinical trials and drug approvals for PROTACs.
  • Reliance on partnerships, like with Pfizer, poses risks if collaborations face challenges.

What makes Arvinas unique

  • Arvinas uses PROTAC technology to target disease-causing proteins for degradation.
  • The company focuses on innovative therapies for cancer and neurodegenerative disorders.
  • Arvinas collaborates with major pharmaceutical companies for drug development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
BioSpace
Mar 28th, 2025
Arvinas Announces Oral Presentation At 2025 International Conference On Alzheimer'S & Parkinson'S Diseases

– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria.ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy.Presentation details are as follows:Session Title: First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Males (ID:1963)Session Type: Symposium: LRRK2, Alpha-Synuclein, Parkin: Diagnosis and Therapeutic Targets (ID:83)Date: Friday, April 4, 2025Lecture Time: 3:20 p.m. - 3:35 p.m. CETThe full abstract can be accessed via the AD/PD 2025 online interactive program.About ARV-102ARV-102 is an oral, brain penetrant investigational PROTAC designed to degrade Leucine-rich repeat kinase 2 (LRRK2) which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 have been implicated in the pathogenesis of neurological diseases including and Parkinson’s disease and progressive supranuclear palsy.About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins

PharmiWeb
Mar 12th, 2025
Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefitin a Phase 3 trial –NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population

Investing.com
Jan 10th, 2025
Arvinas outlines 2025 clinical trial plans for breast cancer drug

In a corporate update, Arvinas announced the appointment of Alex Santini as interim Chief Commercial Officer, effective January 17, 2025.

Hartford Business Journal
Dec 18th, 2024
New Haven-based Arvinas to expand Science Park footprint; renews leases

Arvinas said it will also add 1,500 square feet of space at 5 Science Park for a total of 64,000 square feet.

TipRanks
Jun 24th, 2024
Arvinas Appoints Andrew Saik as CFO with Equity Incentives

Arvinas appoints Andrew Saik as CFO with equity incentives.

INACTIVE